Biomarker-driven and molecularly targeted therapies for pancreatic adenocarcinoma

DB Zhen, A Coveler, Silvia Zanon, M Reni, EG Chiorean

Research output: Contribution to journalArticlepeer-review


Pancreatic ductal adenocarcinoma (PDAC) remains a deadly disease with few effective treatment options. Our knowledge of molecular alterations in PDAC has significantly grown and helped identify new therapeutic targets. The success of immune checkpoint inhibition in mismatch repair deficient tumors, PARP inhibitors for tumors with DNA repair defects, and targeting hyaluronan with PEGPH20 in patients with high expressing (hyaluronan-high) tumors are examples of promising biomarker-driven therapies. We review the major biological mechanisms in PDAC and discuss current and future directions for molecularly targeted therapies in this disease. © 2018 Elsevier Inc.
Original languageEnglish
Pages (from-to)107-115
Number of pages9
JournalSeminars in Oncology
Issue number3
Publication statusPublished - 2018


Dive into the research topics of 'Biomarker-driven and molecularly targeted therapies for pancreatic adenocarcinoma'. Together they form a unique fingerprint.

Cite this